Merck says will not seek
approval of cholesterol treatment
Send a link to a friend
[October 12, 2017] (Reuters)
- Merck & Co Inc said on Wednesday it will
not seek regulatory approval for its experimental cholesterol drug,
anacetrapib, as the clinical profile of the treatment does not support
In August, a large study on anacetrapib found that the treatment cut
the risk of heart attack and death by a modest 9 percent, while
causing a build up of the drug in fat tissue, leaving its commercial
The treatment is part of a class known as CETP inhibitors designed
to raise HDL, the so-called good cholesterol.
On Wednesday, the company said it will not submit an application for
marketing approval after reviewing the clinical profile of the drug.
A little over a decade ago, CETP inhibitors were hailed as the next
big heart drug but companies including Pfizer Inc, Eli Lilly and
Roche eventually scrapped development programs amid lack of efficacy
or safety issues.
(Reporting by Ankur Banerjee in Bengaluru; Editing by Shounak
[© 2017 Thomson Reuters. All rights
Copyright 2017 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.